Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The primary objective assess the clinical activity of combination doxorubicin-containing
chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic
chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to
assess the toxicity of this therapeutic strategy
Phase:
Phase 2
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)